Manufacturing for ultra-rare diseases is different. Volumes are small. Molecules are often highly potent. The margin for error is zero.
Quotient Sciences has announced an extended commercial supply partnership with Ipsen to manufacture Sohonos (palovarotene), a treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare condition affecting fewer than 1,000 people worldwide.
Sohonos (palovarotene) received approval from the U.S. Food and Drug Administration in 2023. FOP is a devastating genetic disorder in which soft tissues progressively turn into bone. Treatment options are extremely limited, making reliable commercial supply critical.
Palovarotene is a highly potent molecule, requiring advanced containment and specialized handling during manufacturing to ensure:
As part of the partnership, Ipsen has invested in new equipment at Quotient Sciences’ Boothwyn, PA facility. Key additions include:
These upgrades expand the site’s ability to manufacture highly potent APIs (HPAPIs) with occupational exposure limits (OELs) at or below 1 µg/m³.
Large-scale CDMOs often prioritize high-volume commercial products.
Ultra-rare therapies require a different model:
The extended partnership ensures sustained commercial supply of Sohonos while strengthening Quotient Sciences’ ability to support other highly potent, niche products.
The new investments enable:
For rare disease communities, supply reliability is not optional. It is essential.
Marlene Leuenberger, Vice President and General Manager, Philadelphia at Quotient Sciences, described the investment as a reinforcement of the company’s commitment to ultra-rare disease patients.
By expanding containment technology and manufacturing capabilities, the company aims to ensure sustained access to critical therapies like Sohonos while supporting partners developing specialized, highly potent compounds.
Quotient Sciences operates as an integrated CRDMO, offering services across drug development, clinical testing, and commercial manufacturing. Its flagship platform, Translational Pharmaceutics, integrates:
The model is designed to accelerate development timelines while maintaining manufacturing continuity from early development through commercialization.
Ultra-rare diseases often face two major hurdles:
This partnership addresses the second.
By investing in advanced containment systems and HPAPI manufacturing capacity, Quotient Sciences and Ipsen are reinforcing the infrastructure needed to support therapies for some of the world’s rarest conditions. For patients with FOP, continuity of supply can make all the difference.